Cover Image
市場調查報告書

Alios BioPharma, Inc.:產品平台分析

Alios BioPharma, Inc. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 276014
出版日期 內容資訊 英文 28 Pages
訂單完成後即時交付
價格
Back to Top
Alios BioPharma, Inc.:產品平台分析 Alios BioPharma, Inc. - Product Pipeline Review - 2014
出版日期: 2014年09月22日 內容資訊: 英文 28 Pages
簡介

Alios BioPharma, Inc.是臨床階段上的治療藥開發生物製藥公司,致力於研發呼吸道融合瘤病毒和流感,鼻病毒,冠狀病毒,C型肝炎病毒等病毒感染治療藥。

本報告提供Alios BioPharma, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Alios BioPharma, Inc.的基本資料

  • Alios BioPharma, Inc.概要
  • 主要資訊
  • 企業資料

Alios BioPharma, Inc.:R&D概要

  • 主要的治療範圍

Alios BioPharma, Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Alios BioPharma, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

Alios BioPharma, Inc.:藥物簡介

  • ALS-8176
  • AL-335
  • AL-516
  • ALS-8112
  • Nucleozin
  • Small Molecules for Rhinovirus Infections
  • Small Molecules to Inhibit RNA-Dependent RNA Polymerase for Influenza
  • Small Molecules to Target Viral RNA Polymerase for RSV Infections

Alios BioPharma, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Alios BioPharma, Inc.:最近的開發平台趨勢

Alios BioPharma, Inc.:暫停中的計劃

Alios BioPharma, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06361CDB

Summary

Global Markets Direct's, 'Alios BioPharma, Inc. - Product Pipeline Review - 2014', provides an overview of the Alios BioPharma, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Alios BioPharma, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Alios BioPharma, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Alios BioPharma, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Alios BioPharma, Inc.'s pipeline products

Reasons to buy

  • Evaluate Alios BioPharma, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Alios BioPharma, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Alios BioPharma, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Alios BioPharma, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Alios BioPharma, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Alios BioPharma, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Alios BioPharma, Inc. Snapshot
    • Alios BioPharma, Inc. Overview
    • Key Information
    • Key Facts
  • Alios BioPharma, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Alios BioPharma, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Alios BioPharma, Inc. - Pipeline Products Glance
    • Alios BioPharma, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Alios BioPharma, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Alios BioPharma, Inc. - Drug Profiles
    • ALS-8176
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AL-335
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AL-516
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALS-8112
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Nucleozin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Rhinovirus Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit RNA-Dependent RNA Polymerase for Influenza
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Target Viral RNA Polymerase for RSV Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Alios BioPharma, Inc. - Pipeline Analysis
    • Alios BioPharma, Inc. - Pipeline Products by Target
    • Alios BioPharma, Inc. - Pipeline Products by Route of Administration
    • Alios BioPharma, Inc. - Pipeline Products by Molecule Type
    • Alios BioPharma, Inc. - Pipeline Products by Mechanism of Action
  • Alios BioPharma, Inc. - Recent Pipeline Updates
  • Alios BioPharma, Inc. - Dormant Projects
  • Alios BioPharma, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Alios BioPharma, Inc., Key Information
  • Alios BioPharma, Inc., Key Facts
  • Alios BioPharma, Inc. - Pipeline by Indication, 2014
  • Alios BioPharma, Inc. - Pipeline by Stage of Development, 2014
  • Alios BioPharma, Inc. - Monotherapy Products in Pipeline, 2014
  • Alios BioPharma, Inc. - Phase II, 2014
  • Alios BioPharma, Inc. - Preclinical, 2014
  • Alios BioPharma, Inc. - Pipeline by Target, 2014
  • Alios BioPharma, Inc. - Pipeline by Route of Administration, 2014
  • Alios BioPharma, Inc. - Pipeline by Molecule Type, 2014
  • Alios BioPharma, Inc. - Pipeline Products by Mechanism of Action, 2014
  • Alios BioPharma, Inc. - Recent Pipeline Updates, 2014
  • Alios BioPharma, Inc. - Dormant Developmental Projects,2014

List of Figures

  • Alios BioPharma, Inc. - Pipeline by Top 10 Indication, 2014
  • Alios BioPharma, Inc. - Pipeline by Stage of Development, 2014
  • Alios BioPharma, Inc. - Monotherapy Products in Pipeline, 2014
  • Alios BioPharma, Inc. - Pipeline by Top 10 Target, 2014
  • Alios BioPharma, Inc. - Pipeline by Top 10 Route of Administration, 2014
  • Alios BioPharma, Inc. - Pipeline by Top 10 Molecule Type, 2014
  • Alios BioPharma, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top